BOSTON, MA – August 11, 2026 (STL.News) Veloxis Pharmaceuticals Inc. has agreed to pay more than $46 million to resolve criminal and civil allegations that it used illegal kickbacks to boost prescriptions of its kidney transplant drug, Envarsus XR, in one of the Justice Department’s most significant healthcare fraud enforcement actions of the year. The resolution also includes what federal officials describe as the largest recovery ever obtained under the federal Physician Payments Sunshine Act since the law took effect in 2010.
The Cary, North Carolina-based pharmaceutical company entered into a three-year Deferred Prosecution Agreement (DPA) with the U.S. Department of Justice after prosecutors filed a criminal information in the U.S. District Court for the District of Massachusetts alleging that the company conspired to violate the federal Anti-Kickback Statute.
Under the agreement, Veloxis will pay a criminal penalty of approximately $10.04 million, resolve related civil allegations for $34.45 million under the False Claims Act, and pay an additional $1.55 million to settle allegations involving violations of the Open Payments Program, commonly known as the Sunshine Act. Together, the payments exceed $46 million.
According to federal prosecutors, Veloxis allegedly provided healthcare professionals with expensive meals, alcoholic beverages, luxury resort accommodations and other items of value to induce physicians and other healthcare...
A VIRAL post on X (formerly Twitter) by user @AmodaOluwaseun claimed that Peter Obi, presidential candidate of the Nigeria Democratic Congress (NDC) and former governor of Anambra State, served as...